Johnson & Johnson (JNJ)

135.31
1.26 0.92
NYSE : Health Care
Prev Close 136.57
Open 135.33
Day Low/High 135.10 / 136.27
52 Wk Low/High 109.32 / 137.08
Volume 6.77M
Avg Volume 5.60M
Exchange NYSE
Shares Outstanding 2.69B
Market Cap 367.90B
EPS 6.00
P/E Ratio 22.95
Div & Yield 3.36 (2.50%)

Latest News

Stocks Are Guilty by Association: Cramer's 'Mad Money' Recap (Thursday 7/20/17)

Stocks Are Guilty by Association: Cramer's 'Mad Money' Recap (Thursday 7/20/17)

Jim Cramer says these market rotations are crushing good stocks that don't deserve it.

Cramer: Rotations Hit Companies That Don't Deserve It

Cramer: Rotations Hit Companies That Don't Deserve It

Case in point: Home Depot and Lowe's.

Investors Should Ignore Washington: Cramer's 'Mad Money' Recap (Tuesday 7/18/17)

Investors Should Ignore Washington: Cramer's 'Mad Money' Recap (Tuesday 7/18/17)

Investors need to focus on earnings and not be distracted by the circus in Washington, Jim Cramer says.

Market Can Rally Again … Can't It?

Non-FANG stocks aren't looking too sharp.

Johnson & Johnson Is Ready to Break Out in a Big Way Despite Lackluster Sales Growth

Johnson & Johnson Is Ready to Break Out in a Big Way Despite Lackluster Sales Growth

Shares of Johnson & Johnson post-earnings are rumbling towards a major breakout.

Cramer: We Need a Vaccine for Washington

Cramer: We Need a Vaccine for Washington

It's difficult for even the best companies to resist infection.

Johnson & Johnson Signals It Could Make Additional Divestitures

Johnson & Johnson Signals It Could Make Additional Divestitures

CFO Dominic Caruso said on an earnings call that ongoing reviews of the company's portfolio "suggest we currently have more opportunity to divest some nonstrategic businesses."

Johnson & Johnson Raises Yearly Sales, Profit Outlook

Johnson & Johnson Raises Yearly Sales, Profit Outlook

Sales and earnings are expected to climb in the second half of the year as the company incorporates new acquisitions and launched new products.

Jim Cramer on Netflix, Bank of America, Goldman Sachs, UnitedHealth, Johnson & Johnson, Advanced Micro Devices, IBM and Nvidia

Jim Cramer on Netflix, Bank of America, Goldman Sachs, UnitedHealth, Johnson & Johnson, Advanced Micro Devices, IBM and Nvidia

TheStreet's Action Alerts PLUS Portfolio Manager Jim Cramer weighs in on Tuesday's trending stocks.

Hold Off on Buying This Great American Company, Jim Cramer Explains

Hold Off on Buying This Great American Company, Jim Cramer Explains

Wait a few days before buying Johnson & Johnson.

It's Report Week: Keep an Eye on the Big Companies

It's Report Week: Keep an Eye on the Big Companies

It's Report Week: Keep an Eye on the Big Companies

Stock Futures Lower as Healthcare Repeal-and-Replace Bill Dies

Stock Futures Lower as Healthcare Repeal-and-Replace Bill Dies

Stock futures lower after Senate GOP healthcare bill dies.

5 Things You Must Know Before the Market Opens Tuesday

5 Things You Must Know Before the Market Opens Tuesday

U.S. stock futures are slightly higher on Tuesday, following the collapse of healthcare overhaul in the U.S.

Market Stands at a Make-Or-Break Level: Cramer's 'Mad Money' Recap (Monday 7/17/17)

Market Stands at a Make-Or-Break Level: Cramer's 'Mad Money' Recap (Monday 7/17/17)

Jim Cramer says the earnings results we get this week will determine where stocks are headed for the rest of the quarter.

European Stocks Drift Lower; Dollar Slumps Further After Healthcare Bill Collapse

European Stocks Drift Lower; Dollar Slumps Further After Healthcare Bill Collapse

European stocks are firmly on the back foot.

European Stocks Called Lower: Currencies in Focus Ahead of U.K. Inflation Data

European Stocks Called Lower: Currencies in Focus Ahead of U.K. Inflation Data

U.K. inflation data highlights macro-focused session

Cramer: This Week of Earnings Will Tell Us Just About Everything We Need to Know

Cramer: This Week of Earnings Will Tell Us Just About Everything We Need to Know

Procter & Gamble proxy fight is an intriguing distraction.

Arena Pharma Skyrockets on Heart Disease Data, Stock Could Still Double -Firm Says

Arena Pharma Skyrockets on Heart Disease Data, Stock Could Still Double -Firm Says

The company just beat a bench mark, previously set by Johnson & Johnson.

Valeant Suffers Another Blow After the Approval of Johnson & Johnson's Psoriasis Treatment

Valeant Suffers Another Blow After the Approval of Johnson & Johnson's Psoriasis Treatment

The approval of Johnson & Johnson's psoriasis treatment will have an adverse impact on Valeant in the second half of 2017, Wells Fargo argued.

Dow Scores Record Close as Retail Roars Higher, Walmart Rallies

Dow Scores Record Close as Retail Roars Higher, Walmart Rallies

Upbeat guidance from Target inspires retail rally.

Johnson & Johnson Looks Sick

Johnson & Johnson Looks Sick

JNJ nears a low-risk entry opportunity.

Dow on Track for Record Close as Retail Roars Higher, Walmart Rallies

Dow on Track for Record Close as Retail Roars Higher, Walmart Rallies

Upbeat guidance from Target inspires retail rally.

Healthcare Stocks Sell Off, Retail Rallies on Upbeat Guidance From Target

Healthcare Stocks Sell Off, Retail Rallies on Upbeat Guidance From Target

Upbeat guidance from Target inspires retail rally.

Cramer: 10 Reasons for Today's Rally

Cramer: 10 Reasons for Today's Rally

Days like this remind you why you stay in.

Arena Pharma's Stock Could Still Double Even After Tuesday's Epic Run

Arena Pharma's Stock Could Still Double Even After Tuesday's Epic Run

Big gains could be ahead for investors willing to stick with the stock, according to one firm.

Sanofi Steps Up M&A Activity With $650 Million Purchase of Protein Sciences

Sanofi Steps Up M&A Activity With $650 Million Purchase of Protein Sciences

Sanofi was also recently engaged in two other deals that it lost out on.

Nasdaq Shows Signs of Weakness

Nasdaq Shows Signs of Weakness

While the Dow is trading sideways, Nasdaq downtrend may already have started.